MedTrace Logo

SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

NCT05752461 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 353

Last updated 2025-01-20

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty

Conditions

  • Prevention of Venous Thromboembolism After Knee Arthroplasty

Interventions

DRUG

SHR-2004 injection

low dose subcutaneous injection once

DRUG

SHR-2004 injection

medium dose subcutaneous injection once

DRUG

SHR-2004 injection

high dose subcutaneous injection once

DRUG

Enoxaparin sodium injection

40 mg administered as subcutaneous injection once daily

Sponsors & Collaborators

  • Beijing Suncadia Pharmaceuticals Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-12
Primary Completion
2024-04-12
Completion
2024-06-25

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05752461 on ClinicalTrials.gov